San Diego-dependent Viking Therapeutics marked itself as a serious competitor during the weight loss drug marketplace in February immediately after revealing promising data from the mid-stage trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when specified for a weekly injection and in March the co